Rich Heyman (ARCH)
Rich Heyman joins PMV Pharma, a p53 biotech, as it adds $70 million in Series D
Less than a year after pulling in an impressive $62 million Series C round, PMV Pharma is back at it again.
The Cranbury, NJ-based biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
